inno.N

A new start for the next century, opening a new chapter
in the pharmaceutical business.

2024

• 2024.03

  'K-CAB' finished exports to the Middle East and North Africa (accumulated overseas 45 countries)

• 2024.02

  Published a white paper on social contribution and received the award of outstanding corporation (outstanding corporation in IR activities) in KOSDAQ market disclosure

2023

• 2023.11

  'K-CAB' selects excellent technology in the field of life science for "2023 Industrial Technology Performance" (National Academy of Engineering of Korea)

• 2023.05

  Establishment of the Sustainable Management Committee

• 2023.01

  K-CAB 25mg is launched in Korea

2022

• 2022.12

  Technologies for the manufacturing of K-CAB are exported to Brazil

• 2022.12

  Receives certification for 'ISO 37301' and 'ISO 37001', international standards for compliance management system and corruption prevention

• 2022.10

  K-CAB Tab. enters phase 3 clinical trials in US

• 2022.10

  Approval of product licensing for K-CAB Tab. in Indonesia

• 2022.05

  Agreement is signed for K-CAB to be exported to 7 countries including India

• 2022.05

  Selected as an excellent company for gender equality awarded by the Minister of Employment and Labor

• 2022.04

  K-CAB launches in China

2021

• 2021.12

  Technologies for the manufacturing of K-CAB are exported to U.S.A.

• 2021.10

  Becomes a member of UN Global Compact (UNGC)

• 2021.09

  96 billion won is invested into the establishment of R&D facilities in the Pangyo Second Techno Valley

• 2021.08

  Listed on KOSDAQ

• 2021.07

  Selected among the top 100 Asian companies that are best to work for (hosted by GWP Korea)

• 2021.06

  Technologies for K-CAB in injection form are exported to China

• 2021.01

  Selected among the top 100 companies that are best to work for (hosted by GWP Korea)

• 2021.01

  Agreement for joint promotion and distribution is signed with MSD Korea for vaccines

  (for a total of seven products including Gardasil. Signed in November, 2020)

2020

• 2020. 12

  The Ministry of Industry’s Prize is given at the 22nd Korea Brand Awards (for Condition) 

• 2020. 12

  The Prime Minister’s Prize is given at the Korea New Growth Management Awards

• 2020. 11

  Agreement is signed for Condition to be exported to Taiwan

• 2020. 10

  Agreement is signed for K-CAB to be exported to Singapore

• 2020.08

  Agreement is signed for K-CAB to be exported to Mongolia

• 2020.08

  Construction of the Osong Plant for IV fluids is completed and approved for operations

• 2020.05

  K-CAB is approved for first phase of clinical trials in U.S.A.

• 2020.02

  Company name is changed from CJ Healthcare Co. Ltd. to HK inno.N Corporation

inno.N continues its innovation as it forays
into an increasing number of global markets.

2019

• 2019.12

  Agreement is signed for K-CAB to be exported to the Philippines

• 2019.11

  Receives certification for 'ISO 37001', an international standard for corruption prevention
  Agreement is signed for K-CAB to be exported to Thailand

• 2019.10

  Research center for cell and gene therapy is established

• 2019.09

  Agreement is signed for K-CAB to be exported to Indonesia

• 2019.03

  K-CAB is launched in Korea

• 2019.02

  Grand Prize for novel drug development is awarded at the 20th Korea Novel Drug Development Awards

2018

• 2018.12

  Agreement is signed for K-CAB to be exported to 17 countries in Latin America

• 2018.11

  Awarded as an innovative pharmaceutical firm (Minister of Health and Welfare’s Prize; Prize from the President of the Korea Healthcare Industry Promotion Institute)

• 2018.10

  'Condition’ enters the Mongolian market

• 2018.07

  Approval received from Korean authorities for the use of K-CAB for GERD (30th novel drug to be registered in Korea)

• 2018.04

  Acquired by Kolmar Korea Co. Ltd.

• 2018.01

  Technologies for the manufacturing of 2nd generation EPO (drug to treat anemia) are exported to China
  Acquired grade ‘AA’ in the evaluation by the Fair Trade Commission for autonomous compliance

2017

• 2017.09

  Technologies for the manufacturing of 2nd generation EPO (drug to treat anemia) are exported to Japan

• 2017.05

  Branch office in Vietnam is opened

2016

• 2016.09

  R&D Open Innovation Forum is hosted with venture firms from U.S.A. and Europe invited

• 2016.08

  MOU for volunteering by employees is signed with Seoul Metropolitan Volunteering Center

• 2016.06

  R&D Open Innovation Forum is hosted with venture firms from U.S.A. and Japan invited

• 2016.04

  Day of autonomous compliance is designated (April 1)

• 2016.02

  The Technology Export Prize is awarded at the 17th Korea Novel Drug Development Award (for K-CAB)

2015

• 2015.10

  Technologies for the manufacturing of K-CAB to treat GERD (with Tegoprazan as the active ingredient) are exported to China

2014

• 2014.06

  'Condition' enters the Vietnamese market

• 2014.04

  Separated into CJ Healthcare Co. Ltd.

• 2014.03

  'Condition' is exported to China

2012

• 2012.11

  To mark the 20th anniversary of the launch of ‘Condition’, a new version, ‘Hut Gae(Oriental Raisin) Condition’ is launched

• 2012.06

  Selected as an ‘innovative pharmaceutical firm’ certified by the Ministry of Health and Welfare

• 2012.05

  The Osong Plant receives the ‘Beautiful Architecture’ Prize by Cheongwon-Gun Office

2011

• 2011.12

  Anti-hangover beverage ‘Condition’ is selected as a ‘world-class product’ by the Ministry of Industry

2010

• 2010.12

  The construction of the Osong Plant for manufacturing finished pharmaceutical products of global is completed
  Well-being beverage ‘Oriental Raisin Water (Hutgaesoo)’ is launched

• 2010.03

  The API production building for orally administered drugs is completed at the Daeso Plant

With continuous research, development and investment,
inno.N is committed to bringing further progress
to the Korean pharmaceutical industry.

2009

• 2009.09

  An agreement for joint promotion and joint marketing is signed with MSD Korea for 'Singulair' and launched `Lukio`

2008

• 2008.07

  Groundbreaking for the Osong Plant (150 billion won is invested)

2006

• 2006.08

  Acquires and merges with Hanil Pharmaceutical

2003

• 2003.06

  ‘Pseudovaccin’, a vaccine for Pseudomonas aeruginosa, is registered as Korea’s 7th novel drug

2000

• 2000.02

  Korea’s first sales organization dedicated to anti-cancer drugs is launched

With the launch of home-grown pharmaceutical products,
inno.N opens a new chapter in the industry.

1999

• 1999.03

  'Epokine' receives the Chang Yeongsil Prize

• 1999.02

  The Daeso Plant receives certification for outstanding compliance with standards for the production and quality management of active pharmaceutical ingredients
  (i.e. certification for BGMP, or Bulk Good Manufacturing Practices)

1998

• 1998.02

  'Epokine', a new drug to treat anemia, is launched (the first of its kind in Korea and the third to be launched worldwide)

1997

• 1997.05

  Successful in-house development of the vaccine for the varicella-zoster virus

• 1997.04

  Vaccine for Pseudomonas aeruginosa receives the Prime Minister’s Prize at the Competition for On-the-Job Inventions
  'Legiofree' acquires the KT mark recognizing new home-grown technologies

1995

• 1995.09

  Injection ‘Citopcin’ receives the Chang Yeongsil Prize

1994

• 1994.05

  World’s first vaccine for Pseudomonas aeruginosa is developed

1992

• 1992.11

  Anti-hangover beverage ‘Condition’ is launched

• 1992.05

  New plant for IV fluids is completed

1990

• 1990.03

  '7-ACA', an active pharmaceutical ingredient for antibiotics, is launched
  Daeso Plant is completed

With the establishment of a comprehensive research institute in 1984,
the company starts its pharmaceutical business in earnest.

1986

• 1986.12

  The Icheon Plant completes its construction

1985

• 1985.12

  'Hepaxin-B', a vaccine for Hepatitis B is developed using domestic technologies only and launched in the market

1984

• 1984.06

  The establishment of a comprehensive research institute marks the company’s foray into the pharmaceuticals business